A lack of toxicity and the shrinking of tumors were at the heart of new interim data produced from a two-stage phase II study by Relay Therapeutics Inc. The company reported that the oral small molecule RLY-4008, designed to elicit responses across a broad spectrum of resistance mutations and in multiple tumor types, selectively inhibited fibroblast growth factor receptor (FGFR) 2 in ways that are not limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4).
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research virtual International Conference on Molecular Targets and Cancer Therapeutics, including: Aileron, Amgen, Amunix, Bridgebio, Clovis, Cogent, Curis, Deciphera, Essa, Forma, Gennao, Hummingbird, Ikena, Immunome, IMV, Kineta, Kinnate, Medicenna, Monte Rosa, Nuvalent, Oric, Phio, Prelude, Relay, Salarius, Second Genome, Spectrum, Turning Point.
RSS
